NEW YORK – China-based precision oncology firm Genetron Health and CRO DMed Biopharmaceutical said Thursday that they have signed a partnership agreement to create what they envision as a "one-stop" shop for drug research and development services for biopharmaceutical companies in both China and the US.
Under the agreement, Genetron Health will provide its technology and expertise in precision oncology, including central laboratory services, screening for new drug targets or biomarkers, companion diagnostic development, and clinical trial patient screening. DMed will lend itself to areas like R&D design, clinical operations, data management and statistical analysis, and regulatory affairs.
Genetron Health said it has five laboratories in China that have passed external quality assessment by the country's National Center for Clinical Laboratories. The company's Beijing lab is also CAP accredited and CLIA certified, and it has a CLIA lab in Maryland under construction to serve global pharmaceutical companies in a US location. The firm has commercialized assays across multiple molecular technology platforms, including NGS, digital PCR, and quantitative PCR.
Supporting its CRO efforts, DMed has offices in cities including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels. In 2019, the company completed the acquisition of Target Health, a full-service New York-based CRO.
"Joining forces with strategic partners such as DMed, Genetron Health's capability will be further utilized to provide more comprehensive and flexible R&D solutions for domestic and global companies in oncology drug development," Sizhen Wang, cofounder and CEO of Genetron Health, said in a statement.
Financial terms of the agreement were not disclosed.